Novartis $245 million pay-out is latest reminder of pay-for-delay risks

Novartis $245 million pay-out is latest reminder of pay-for-delay risks

Patent litigation settlements face increasingly dangerous antitrust pitfalls

Unlock unlimited access to all IAM content